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Abstract
Background: A preventive role of selenium on the risk of diabetes has been reported and ascribed to the “insulin-
like” activity of selenium and the antioxidant properties of the selenoenzymes. By contrast, data from cross-
sectional studies and clinical trials have suggested an adverse effect of high selenium status and selenium
supplementation on type-2 diabetes risk. Given these controversial results, we investigated prospectively the
relationship between baseline plasma selenium concentration and occurrence of dysglycemia (impaired fasting
glucose or type 2 diabetes) in an elderly French cohort.
Methods: The Epidemiology of Vascular Ageing (EVA) study (n = 1389, 59-71 years) is a 9-year longitudinal study
in which, fasting plasma glucose was measured at baseline, 2, 4 and 9 years. Analyses were performed on 1162
participants with complete data.
Results: At baseline plasma selenium mean levels were 1.08 (0.21) μmol/l in men and 1.10 (0.20) μmol/l in women.
During the 9-year follow-up, 127 cases of dysglycemia occurred. A significant interaction was found between
plasma selenium and sex. Risk of dysglycemia was significantly lower in men with plasma selenium in the highest
tertile (T3:1.19-1.97) compared to those in the lowest tertile (T1:0.18-1.00) [HR = 0.48 (0.25-0.92)], but no significant
relationship was observed in women. After controlling for socio-demographic factors, lifestyle factors, cardiovascular
diseases, body mass index, hypertension and lipid profile, plasma selenium remained marginally significantly
associated with occurrence of dysglycemia in men [T3 vs. T1, HR = 0.50 (0.24-1.04)] and unrelated in women.
Conclusions: This prospective study suggests a sex-specific protective effect of higher selenium status at baseline
on later occurrence of dysglycemia.
Background
Type 2 diabetes is a common burden in the elderly [1].
In this context, identifying nutrients that could help
reduce diabetes in an elderly population is a worthy
public-health aim.
Selenium is an essential trace element. Its importance
is underlined by the fact that it is the only trace element
to be specified in the genetic code - as selenocysteine.
Selenium is a key component of several functional
selenoproteins [e.g., glutathione peroxidases (GPx),
thioredoxin reductases, iodothyronine deiodinases and
selenoprotein P] that protect tissues and membranes
from oxidative stress and control the cell redox status
[2]. Evidence from in vivo and in vitro studies suggests
that selenium could enhance insulin sensitivity by med-
iating insulin-like actions [3,4].
Results from human studies on selenium and diabetes
are conflicting. Two studies found lower serum sele-
nium concentrations in diabetic patients than in control
subjects [5,6] while in the Health Professionals Follow-
up Study, toenail concentrations were lower in diabetic
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higher serum selenium concentration was associated
with a higher prevalence of diabetes [8,9], higher fasting
plasma glucose and glycosylated hemoglobin levels [9]
in the National Health and Nutrition Examination Sur-
vey [8,9]. Randomized trials again showed discordant
findings: in the SUVIMAX trial, despite positive correla-
tions between plasma selenium and plasma glucose both
at baseline and at the end of the follow-up, no effect of
supplementation with a mixture of antioxidants, includ-
ing 100 μg/day selenium, on plasma glucose levels was
found after 7.5 years of follow-up, was found [10]. A
recently-published analysis of Nutritional Prevention of
Cancer Trial data showed that supplementation with
200 μg/d selenium as high-selenium yeast for 7.7 years
increased the risk of self-reported type 2 diabetes [11].
Given these controversial results, we investigated pro-
spectively the relationship between baseline plasma sele-
nium concentration and occurrence of diabetes or
impaired fasting glucose in a cohort of healthy elderly
French men and women followed up for 9 years.
Methods
Subjects
The EVA (Epidemiology of Vascular Ageing) study is a
9-year follow-up longitudinal study primarily aimed at
studying cognitive impairment and vascular ageing
[12,13]. At baseline (EVA0, 1991-1993), 1389 volunteers
(574 men and 815 women, mean age 65 yr) residing in
the town of Nantes (Western France) were recruited.
The subsequent follow-up waves with biochemical mea-
surements were EVA2 (2-year follow-up, n = 1272),
EVA3 (4-year follow-up, n = 1188) and EVA6 (9-year
follow-up, n = 781). The study protocol was approved
by the Ethical Committee of the University Center Hos-
pital of Kremlin-Bicêtre, France. Signed, informed con-
sent was obtained from all participants at enrolment.
The present analyses relate to the 1162 participants
who were normoglycemic [fasting blood glucose (FBG)
≤ 6.1 mmol/L] and not using anti-diabetic drugs at
baseline, and for whom plasma selenium measurements
were available. Characteristics of the 635 participants
who completed the 9-year follow-up were compared to
t h o s eo ft h e5 2 7w h od i dn o t ,o fw h o m1 0 1h a dd i e d .
T h el a t t e rw e r em o r el i k e l yt ob ec u r r e n to rf o r m e r
smokers (43.4% vs. 37.5%, P = 0.04), to have higher
baseline diastolic blood pressure (79.5 ± 1.0 vs. 78.2 ±
0.7 mm Hg, P = 0.03); there were no other significant
differences between the groups.
According to the WHO definition [14], participants
with FBG ≥ 7 mmol/L or who used anti-diabetic drugs
were defined as diabetic; participants with FBG between
6.1 and 7 mmol/L were considered as having impaired
fasting glucose (IFG). Dysglycemia was defined as the
presence of IFG or diabetes.
Methods
A baseline questionnaire recorded information on sex,
age, education (≤ primary school/> primary school),
smoking habits (current/ex-smoker/non-smoker), alco-
hol intake (≥ 20 ml/< 20 ml per day), use of lipid-lower-
ing drugs, use of antihypertensive drugs and history of
cardiovascular diseases (CVD) (myocardial infarction,
angina pectoris and stroke). Height and weight were
measured and body mass index (BMI) was calculated as
weight (kg) divided by height squared (m
2). Two inde-
pendent measures of systolic and diastolic blood pres-
sure were taken with a digital electronic tensiometer
after a 10-minute rest, from which the means were
calculated.
Blood samples were drawn between 8.30 am and 9.30
am after a 12-hour fast. Analytical procedures for the
determination of glucose, LDL-cholesterol, HDL-choles-
terol and triglycerides, thiobarbituric acid reactive sub-
stance concentrations (TBARs) and erythrocyte GPx
activity (only measured at EVA2) have been described
elsewhere [13]. Plasma selenium was determined using
electrothermal atomic absorption spectrometry (Perkin
Elmer 5100 ZT, Norwalk, CT, USA) [15].
Statistical analysis
Plasma selenium was categorized by tertiles. Survival
analyses by an actuarial method were used to assess the
occurrence of dysglycemia according to tertile of plasma
selenium at baseline [S(t)]. The association between
plasma selenium tertile and onset of dysglycemia was
determined by Cox proportional hazards regression
models. The proportional hazards assumption was veri-
fied by adding a time-dependent variable to the model.
Additionally to age, analyses were adjusted for educa-
tion, smoking habits, alcohol intake, LDL-cholesterol,
HDL-cholesterol, triglycerides, use of lipid-lowering
drugs, systolic and diastolic blood pressure, use of anti-
hypertensive drugs, history of CVD and BMI. All inter-
actions between plasma selenium and other variables
were tested. The presence of a significant interaction
with sex (p < 0.001) led us to carry out analyses sepa-
rately in men and women.
To explore whether relationships with plasma sele-
nium might be related to a redox effect of selenopro-
teins, analyses were performed to assess the relationship
between markers of antioxidant status i.e. TBARs and
erythrocyte GPx activity and risk of dysglycemia. The
level of statistical significance was set at p = 0.05, and
marginally significance was defined by 0.05> p < 0.10.
Statistical analyses were performed using SAS software
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Results
The median and range values for each tertile of plasma
selenium were 0.90 μmol/L (0.18-1.00) for T1 (<33
rd),
1.09 μmol/L (1.01-1.18) for T2 (≥ 33
rd <66
th), 1.32
μmol/L (1.19-1.97) for T3 (≥ 66
th). Plasma selenium
concentrations did not differ significantly between men
and women. Factors associated with plasma selenium
are shown separately for men and women in Additional
file 1. No significant association was found between
selenium tertile and age, education, alcohol intake, LDL
cholesterol, triglyceride, use of hypertensive drugs, blood
pressure and BMI in either gender. While in women,
smoking habit was not associated with selenium status,
unexpectedly, men who were current or former smokers
were more likely to be in the top tertile of selenium.
Regarding blood lipids, HDL-cholesterol increased sig-
nificantly across selenium tertiles in women but not in
men. While LDL-cholesterol and triglyceride were not
associated with Se, users of lipid-lowering drugs were
more likely to have high levels of selenium both in men
and women.
During the 9-year follow-up, 127 new cases of dysgly-
cemia occurred of which 15.8% were in men and 7.8%
in women (p < 0.0001), including 29 cases of type 2 dia-
betes. Among them, 64 cases (including 9 of diabetes)
occurred during the first two years of follow-up, 40
(including 10 of diabetes) occurred between EVA2 and
EVA3, and 23 (including 10 of diabetes) occurred
between EVA3 and EVA6.
Occurrence of dysglycemia according to baseline ter-
tile of plasma selenium showed that in men, the lower
the tertile (T), the greater the occurrence of dysglycemia
(Figure 1a) (results from the log rank test: T1 vs. T3:
p = 0.05, T1 vs. T2: p = 0.65, T2 vs. T3: p = 0.13),
whereas in women, the occurrence of dysglycemia was
comparable in all three tertiles (Figure 1b). Analyses of
the relationship of plasma selenium tertile and other
population characteristics to the onset of dysglycemia
were carried out separately for men and women. Results
of unadjusted Cox models (Additional file 2) confirmed
that risk of dysglycemia was significantly lower in men
with plasma selenium in T3 compared to those with
plasma selenium in T1 [T3 vs.T 1 ,h a z a r dr a t i o( H R )=
0.48 (95% confidence interval: 0.25-0.92)] but this was
not the case in women [T3 vs. T1, HR = 0.89 (0.46-
1.72)]. These associations were not much attenuated
after adjustment for socio-demographic factors (age,
education), smoking, alcohol consumption, health para-
meters (BMI, diastolic and systolic blood pressure, use
of hypertensive drugs, LDL-cholesterol, HDL-choles-
terol, triglycerides, CVD history, use of lipid-lowering
drugs), with a marginally significant association remain-
ing in men [T3 vs. T1, HR = 0.50 (0.24-1.04)] but not in
women [T3 vs. T1, HR = 1.13 (0.55-2.32)].
In supplementary analyses, we assessed the relation-
ship between markers of antioxidant status - TBARs
and GPx activity - and the risk of dysglycemia in partici-
pants for whom these markers were available (n = 846).
After adjustment for potential confounders, we showed
that none of the oxidative stress markers was signifi-
cantly associated with the risk of developing dysglycemia
in either sex over the 9-year period [for erythrocyte GPx
activity (by 1UI/I), HR = 0.99 (0.96; 1.02), p = 0.57 in
men and HR = 1.02 (0.99; 1.05), p = 0.19 in women and
for TBARs (by 1 μmol/L), HR = 1.79 (0.78-4.07) p =
0.17 in men and 1.18 (0.53-2.62), p = 0.69 in women].
Discussion
Our results showed that for French elderly males, having
plasma selenium concentrations in the top tertile of the
population distribution (1.19-1.97 μmol/L) was signifi-
cantly associated with a lower risk of developing dysgly-
cemia over the following nine years. This association
remained marginally statistically significant after taking
into account socio-demographic and lifestyle factors,
C V Dh i s t o r y ,B M I ,b l o o dp r e s s u r e ,H D L - c h o l e s t e r o l ,
LDL-cholesterol and triglycerides. Plasma selenium was
not associated with risk of dysglycemia in women,
where only high systolic blood pressure, high BMI, alco-
hol intake, use of lipid-lowering drugs and low HDL-
cholesterol were related to the incidence of dysglycemia.
Epidemiological studies that have investigated specifi-
cally the association between selenium and diabetes are
scarce. Two case-control studies conducted in Europe
on a limited number of subjects showed significantly
lower selenium concentrations in adult patients with
type 2 diabetes compared to controls [5,6]. Similar
findings from a cross-sectional analysis of the Health
Professionals Follow-up Study showed lower toenail
selenium concentrations among men with diabetes
(with or without CVD) than among healthy control
participants [7]. However, such studies do not allow us
to determine whether low selenium was a cause or a
consequence of the disease process. Indeed, in inflam-
matory conditions, decreased selenoprotein expression -
especially of the plasma protein, selenoprotein P - is
known to occur and can account for the lower plasma
selenium concentration observed in such states [16]. A
large cross-sectional analysis within the US Third
National Health and Nutrition Examination Survey
(8,876 adults, ≥ 20 years of age) showed that the highest
quintile of serum selenium (≥ 137.66 ng/ml = 1.74
μmol/L) had a significantly increased prevalence of
diabetes compared to those in the lowest quintile
(<111.62 ng/ml = 1.41 μmol/L), though rather
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in the three middle quintiles [8]. The recent report
from Laclaustra et al. confirms those findings i.e. an
increased risk of type 2 diabetes associated with
serum selenium concentration in the US middle-aged
population (917 adults, ≥ 40 years of age) [9].
Randomized controlled trials have also shown con-
flicting results. In the SUVIMAX trial, no effect of
combined supplementation with antioxidants, including
selenium (100 μg/day as high-selenium yeast) was
observed on fasting plasma glucose after 7.5 years of
follow-up, despite a positive association between
Figure 1 Occurrence of dysglycemia by tertile of plasma selenium in men (a) and in women (b). Tertile 1: 0.18-1.00 μmol/L (median
value = 0.90 μmol/L). Tertile 2:1.01-1.18 μmol/L (median value = 1.09 μmol/L). Tertile 3: 1.19-1.94 μmol/L (median value = 1.29 μmol/L).
Black circle: Tertile 1; White square: Tertile 2; Grey tangle: Tertile 3.
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whole population [10]. However, the SUVIMAX trial
was a multi-antioxidant supplementation trial and it is
impossible to isolate the effect of selenium from that
of other antioxidants administered. More recently, the
Selenium and Vitamin E Cancer Prevention Trial
(SELECT) that recruited 35,533 men from the United
States, Canada, and Puerto Rico with a median follow-
up of 5.5 years, reported a small (though non-signifi-
cant) increased risk of type 2 diabetes in those supple-
mented with selenium (200 μg/d from L-
selenomethionine) rather than placebo [RR = 1.07
(0.94-1.22), p = 0.16] [17]. The effect of long-term
selenium supplementation as a single nutrient on the
incidence of type 2 diabetes was also investigated by
Stranges et al. [11]. Their secondary analysis of the
Nutritional Prevention of Cancer randomized trial
showed a higher cumulative incidence of type 2 dia-
betes during 7.7 years of follow-up in participants
receiving selenium (200 μg/day as high-selenium yeast)
than in those receiving placebo. Interestingly, when
results were examined by tertile of baseline plasma
selenium, the increased risk was only observed in the
top tertile (mean baseline plasma selenium >1.54
μmol/L). It should be noted that the median concen-
tration of selenium in the highest tertile of our study
was 1.32 μmol/L, equivalent to their lowest tertile (≤
1.33 μmol/L). It is of course well known that selenium
intakes in France, and more generally in Europe, are
considerably lower than in the United States [18,19].
Thus, it is possible that the difference between our
results and those of Stranges could be partly explained
by a selenium-status effect. Another point for consid-
eration is that in this secondary analysis of the Nutri-
tional Prevention of Cancer trial, the diabetes cases
were not identified through measurement of fasting
blood glucose, but were based on self-report and medi-
cal records. To our knowledge, our study is the first
prospective observational study to show that healthy
elderly men with baseline plasma selenium between
1.19-1.97 μmol/L had a significantly lower risk of
developing dysglycemia over a 9-year follow-up period
compared to those with plasma selenium concentration
below 1.00 μmol/L. This suggests that optimal levels of
selenium may reduce the risk of developing hypergly-
cemia or type 2 diabetes in men.
T h em e c h a n i s mb yw h i c hs e l e n i u mm a yp r o t e c t
against dysglycemia in the present study is unclear but
may involve the selenoenzymes, the activity of which
would certainly not be optimal at the plasma selenium
concentration range of the bottom tertile in our study
(0.18-1.00 μmol/L) [2]. The fact that markers of antioxi-
dant status available in our study - TBARs and erythro-
cyte GPx activity - were not associated with the risk of
dysglycemia may suggest that functions of selenopro-
teins other than those of antioxidants are more impor-
tant in this context.
Selenium is known to be a trace mineral with a nar-
row range of optimal intake and considerable inter-indi-
vidual variability in terms of metabolic sensitivity [20,21]
which is at least partly due to the existence of poly-
morphisms in selenoproteins [22]. Several plausible
mechanisms underlie both the potential beneficial and
adverse effects of selenium on diabetes [23]. One of the
hypotheses attributes the anti-diabetic mechanism of
selenium species to their insulin-like properties. This
beneficial effect has been observed with selenate and to
a lesser extent with selenite and selenomethionine [3].
Experiments on rat tissues suggest that selenate treat-
ment induces increased phosphorylation of the insulin-
receptor beta subunit and of other downstream proteins
of the insulin-signaling pathway [3]. The anti-diabetic
properties of selenium species would lead to inhibition
of the insulin signal, antagonizing protein tyrosine phos-
phatase 1 B (PTP1B). This protein, in normal physiolo-
gical conditions, is involved in the termination of insulin
signalling and exerts a lipogenic effect. However these
potential mechanisms suggested by animal studies were
observed with high doses of selenate which are toxic in
humans. Other experimental studies have investigated
the potential pro-diabetic mechanisms of selenium
[24-27]. Development of insulin resistance has been
described in mice over-expressing GPx1 [24]. Further-
more, it has been suggested that long-term selenium
supplementation at high doses may increase the risk of
obesity and diabetes by maintaining excessive GPx1
activity that may alter the physiological inhibition
mechanism of PTP1B resulting in permanent inhibition
of insulin signalling and activation of the lipogenic path-
way [24-26].
The reason we observed a protective effect of sele-
nium in men but not in women is not clear. Differences
in risk factors in men and women have been reported
for a number of diseases including type 2 diabetes
[28,29]. Our results clearly show that men are more at
risk of diabetes than women as shown by the higher
percentage of men having known risk factors at baseline,
i.e. smoking, drinking > 20 ml alcohol/day, higher BMI,
blood pressure, FBG, plasma triglycerides and lower
HDL-cholesterol. This sex effect might be attributed to
the better overall antioxidant status of women: we have
previously reported in the EVA study that women had
higher erythrocyte vitamin E and total carotenoid con-
centrations than men [30]. Finally, a considerable num-
ber of studies have provided evidence that males and
females handle selenium differently [31]. Studies have
shown that men and women respond differently to diet-
ary selenium with respect to selenoprotein P and GPx4
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from animal experiments: sexually dimorphic expression
patterns of a number of selenoproteins - GPx1, type I
deiodinase and selenoprotein P - have been found in
liver and kidney of young and old mice [34]. In the light
of such sex-specific findings, it is perhaps not surprising
that we saw an association between selenium tertile and
subsequent risk of dysglycemia in men but not in
women. However, given the fact that the US Third
National Health and Nutrition Examination Survey also
showed a sex specific association with diabetes, but in
the other direction, i.e. with a deleterious effect of high
selenium in men but not in women [8], other studies
are clearly needed to understand the underlying
mechanism of the sex specificity in the selenium-dysgly-
cemia relationship.
Our study has limitations. The EVA study included
volunteers with higher educational status and higher
incomes than most elderly French. However this should
not affect the relationship between plasma selenium and
dysglycemia. More importantly, for reasons of statistical
power (only 29 incident cases of diabetes), we included
IFG in the dysglycemia definition. IFG indicates a risk
for diabetes, but we cannot exclude the possibility that
fasting glucose may have reverted to normal in some
participants which would have resulted in an over-diag-
nosis of dysglycemia. However, this would have wea-
kened rather than strengthened the true association
between selenium and dysglycemia. Another limitation
is that data on intake of selenium supplements were not
available in our study; this means we cannot know
whether subjects with low plasma selenium level at
baseline might have taken selenium supplements after
the baseline. However in the 1990s in France, as com-
pared to the US or the UK, very few people took sele-
nium supplements making it less probable that the
relationship observed between blood selenium and onset
of dysglycemia would be biased by not taking selenium
supplementation into account. Finally, another limitation
is the high rate of attrition in this cohort. Participants
lost to follow-up had lower baseline selenium concentra-
tions. This has probably resulted in an underestimation
of the incidence of dysglycemia and consequently
decreased the power of the study. Despite these limita-
tions, we observed a significantly lower risk of dysglyce-
mia in men in the highest selenium tertile compared to
those in lower tertiles which remained borderline signifi-
cant after adjusting for a large range of potential
confounders.”
Conclusions
In conclusion, our findings added to those of others
clearly underline the need for further studies. We need
to identify the optimal range of selenium status and
intake that will minimize potential adverse effects on
glucose metabolism while optimizing type 2 diabetes
prevention. This may allow us to target a population
that might benefit from selenium supplementation.
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